Supreme Court drug case could restrict development: Lilly, other firms want research exemption confirmed
The U.S. Supreme Court will hear arguments April 20 in a case that Eli Lilly and Co. and other pharmaceutical corporations say could restrict the development of new drugs. The dispute stems from a June 2003 decision by the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. The panel affirmed a district court’s finding that Merck KGaA in Germany infringed upon four of New Jersey-based Integra LifeSciences Holdings Corp.’s licensed patents. At issue is whether pharmaceutical companies…